About half of PD patients with PARK2 mutations were reported to have either homozygous or compound heterozygous exon rearrangements (Hedrich et al., 2004; Lincoln et al., 2003; Oliveira et al., 2003; Spatola & Wider, 2014). Here, PRKN is linked to Parkinson disease.